OCOfelia Coanqui

Ofelia Coanqui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ofelia Coanqui has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ¿Dónde estamos y hacia dónde vamos en el cáncer de pulmón de células no pequeñas avanzado con mutación EGFR?

    by Jessica Meza-Liviapoma, Katia Roque, Marco Gálvez-Niño, Rossana Ruiz, Ofelia Coanqui, Natalia Valdiviezo, Mivael Olivera, Luis Mas

    El cáncer de pulmón de células no pequeñas (CPCNP) continúa siendo una de las principales causas de mortalidad por cáncer a nivel mundial. La identificación de mutaciones accionables, en especial en el gen del receptor del factor de crecimiento epidérmico (EGFR), ha modificado de manera sustancial el abordaje terapéutico de esta enfermedad. Los Inhibidores de tirosina quinasa (TKI) han demostrado mejoras consistentes en supervivencia libre de progresión y supervivencia global frente a la quimioterapia convencional. No obstante, la resistencia adquirida se desarrolla en la mayoría de los casos, ya sea por mutaciones secundarias, activación de vías alternativas como MET o HER2, o transformación histológica. En los últimos años, el manejo del CPCNP con mutación EGFR ha evolucionado hacia estrategias más complejas que incluyen combinaciones en primera línea, esquemas de intensificación con quimioterapia y el uso de anticuerpos biespecíficos. Asimismo, se han desarrollado terapias dirigidas específicas para mutaciones no frecuentes, como las inserciones del exón 20, y recientemente los anticuerpos fármaco-conjugados han ampliado las alternativas terapéuticas en el escenario pososimertinib. El objetivo de esta revisión es actualizar el estado actual del tratamiento del CPCNP avanzado con mutación EGFR y discutir las estrategias emergentes orientadas a superar los mecanismos de resistencia.

  • Open Access

    Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long‐Term Survival

    by Katia Roque, Rossana Ruiz, Renier Cruz, Andrea Ramirez-Aramburú, Eloy Ruiz, Carlos Castaneda, Marco Galvez-Nino, Ofelia Coanqui, Natalia Valdiviezo, Mivael Olivera Hurtado de Mendoza, et al.

    The endodermal sinus tumor (EST), also known as yolk sac tumor, accounts for 20% of germ cell tumor cases, typically occurring in gonadal locations. However, 1%–5% can present with an extragonadal localization. Primary hepatic EST is an extremely rare entity and poses a diagnostic challenge for the appropriate management of this pathology. We present the case of a 34‐year‐old woman who presented with a single hepatic mass associated with elevated alpha‐fetoprotein (AFP) levels. Initially, hepatocellular carcinoma (HCC) was suspected, leading to a right hepatectomy, which resulted in pathology findings consistent with an EST. Following surgery, the patient underwent four courses of BEP chemotherapy, showing a partial response with residual lesions. The patient received two more courses of EP chemotherapy, with a PET CT showing a complete response. At over 5 years of follow‐up, the patient remains clinically stable, with negative tumor markers, no evidence of disease, and leading a normal life. Primary hepatic EST is an infrequent but important differential diagnosis of HCC, particularly in young women without cirrhosis who present with markedly elevated AFP levels. Early biopsy confirmation and multidisciplinary management are essential, as this chemosensitive tumor may achieve long‐term survival with timely systemic treatment.

  • Open Access

    Guía de práctica clínica para estadiaje y tratamiento del cáncer de cuello uterino en estadios tempranos

    by Aldo López-Blanco, Miguel Angel Béjar-Torres, Joan Flaubert Pérez-Villena, Ofelia Coanqui Gonzáles, Katia Roque Pérez, Karintia Ballón Cervantes, Edgar Gustavo Lasteros Ayma, Esperanza Milla Noblega, Patricia Elena Webb-Linares, Juan Carlos Lopez Blanco, et al.

    Introducción. El presente artículo presenta un resumen de la guía de práctica clínica (GPC) sobre el estadiaje y tratamiento del cáncer de cuello uterino en estadios tempranos. Objetivo. Proporcionar a los profesionales de la salud recomendaciones basadas en evidencia para el estadiaje y manejo terapéutico del cáncer de cuello uterino en etapas iniciales. Métodos. Se conformó un grupo elaborador de la guía (GEG), conformado por especialistas clínicos y metodólogos, los cuales formularon preguntas clínicas prioritarias en formato PICO. Se realizaron búsquedas sistemáticas de revisiones sistemáticas y, cuando fue pertinente, de estudios primarios en PubMed, Cochrane Library y Embase, entre enero de 2024 y febrero de 2025. La evidencia seleccionada fue evaluada mediante la metodología Grading of Recommendations Assessment, Development and Evaluation (GRADE) para determinar su certeza. En sesiones deliberativas, el GEG utilizó GRADE para analizar la evidencia y desarrollar las recomendaciones, puntos de buena práctica clínica y flujogramas. La GPC fue aprobada mediante Resolución Directoral N.º 004-2025-CETS/INS. Resultados. La GPC respondió 7 preguntas clínicas, a partir de las cuales se formularon 5 recomendaciones condicionales, 9 puntos de buena práctica clínica y 3 flujogramas. Las recomendaciones formuladas contemplan que para mujeres con cáncer de cuello uterino con enfermedad clínica local que requieran evaluación del compromiso parametrial y ganglionar, se sugiere utilizar la resonancia magnética con contraste. Además, en mujeres con cáncer de cuello uterino en estadio IA1 (con infiltración del espacio linfovascular) a IB2 y IIA1 se sugiere realizar biopsia de ganglio centinela para determinar el compromiso ganglionar. Conclusión. Se emitieron recomendaciones y puntos de buena práctica clínica basados en evidencia para el estadiaje y tratamiento de cáncer de cuello uterino en estadios tempranos.

  • Open Access

    Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru

    by Marco Galvez‐Nino, Rossana Ruiz, Katia Roque, Ofelia Coanqui, Natalia Valdivieso, Mivael Olivera, Apar Kishor Ganti, Luis Mas

    Background: Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti‐epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real‐world setting.Methods: This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti‐EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS).Results: We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathogenic mutation in 39.5% of patients. Only 51.2% of them received anti‐EGFR TKI as institutional treatment. ORR was 58%, after median follow‐up of 32 months, the estimated median PFS was 13.9 months (11.1–16.7 months), and the estimated median OS was 21.7 months (18.5–24.9 months). No differences were found in PFS according to line of treatment or brain metastases at diagnosis (p = 0.46 and p = 0.07, respectively), respect to OS there were no differences line of treatment (p = 0.12), significant difference were found in presence of brain metastases (p = 0.006).Conclusion: Our study demonstrates that erlotinib for advanced NSCLC harboring EGFR‐activating mutations is effective even in patients usually excluded from clinical trial, like those previously exposed to one or more lines of chemotherapy or with brain metastases.


  • Genomic profile by liquid biopsy of Peruvian patients with lung cancer.

    by Marco Galvez-Nino, Katia Roque Perez, Melanie Wendy Castro, Rossana Ruiz, Natalia Valdivieso, Ofelia Coanqui, Mivael Olivera Hurtado de Mendoza, Edgar Amorin, Luis Mas

    E15027 Background: The optimal treatment of advanced NSCLC patients is currently led by genomic profiling with the goal of detecting actionable mutations with an approved targeted therapy. However, tissue DNA samples are not always available to perform this assays. In this context, liquid biopsy has emerged as a valuable tool for providing the best treatment option. Methods: Retrospective study held at Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima - Peru, between January 2019 and September 2021 to assess the genomic profile of 190 newly diagnosed advanced NSCLC patients through liquid biopsy. Blood samples were profiled with the FoundationOne Liquid Biopsy assay. We describe frequency of pathogenic and targetable genetic alterations, as well as the survival outcomes. Genomic and clinical data were recorded from clinical files. Results: The median age was 63 years (26-90), 66.3% were women, 15.3% smokers, 26.3% had exposure to biomass, 22.6% had a first-degree family history of cancer. The most frequent histological type was adenocarcinoma (86.8%). Regarding genomic profile, 183 patients (96.3%) had at least one pathogenic genetic alteration, the most frequent altered genes were TP53 (54.7%), EGFR (50.5%), DNMT3A (17.9%), KRAS (9.5%) and NF1 (6.8%). 116 patients (61%) had a targetable mutation: EGFR Ex19del/ins (27.4%), EGFR L858R/L861Q (17.9%), ALK rearrangements (5.8%), BRAF V600E (3.2%), RET fusions (1.6%), METex14 skipping (1.6%), KRAS G12C (1.6%), ROS 1 (1.1%), and NTRK (0.5%). Of these, 71 patients (65.5%) were able to access target therapy. For the latter, estimated median PFS and OS were 14.0 months (9.3 – 18.6) and 17.8 months (8.2 – 27.4), respectively. Conclusions: Peruvian NSCLC patients represent a population with a high frequency of pathogenic and targetable mutations, being EGFR mutations and ALK rearrangements the most prevalent ones. Despite limited access, a great proportion of patients received target therapy, achieving remarkable survival.